Recent News

• 06.04.2025 - Jefferies Global Healthcare Conference
• 04.23.2025 - Statement of changes in beneficial ownership of securities
• 04.23.2025 - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.23.2025 - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.23.2025 - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.23.2025 - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.21.2025 - Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
• 04.17.2025 - SCHEDULE 13G/A: SCHEDULE 13G/A – Description
• 04.16.2025 - Jefferies Global Healthcare Conference
• 04.07.2025 - Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Recent Filings

• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.21.2025 - 144 Report of proposed sale of securities
• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities